Clinical comparative investigation using intensity-modulated radiotherapy combined with concurrent chemotherapy for the local advanced nasopharyngeal carcinoma
10.3760/cma.j.issn.0254-5098.2009.04.019
- VernacularTitle:调强放疗联合同步化疗对局部晚期鼻咽癌的临床观察
- Author:
Yingchao ZHAO
;
Xiaofang DAI
;
Gang WU
;
Yanxia ZHAO
;
Ming LUO
- Publication Type:Journal Article
- Keywords:
Nasopharyngeal neoplasms;
Intensity modulated radiation therapy;
Chemotherapy;
Tolerance
- From:
Chinese Journal of Radiological Medicine and Protection
2009;29(4):414-417
- CountryChina
- Language:Chinese
-
Abstract:
Objective To research the early effects and side-effects of the local advanced nasopharyngeal carcinoma patients using intensity-modulated radiotherapy(IMRT)combined with concurrent chemotherapy.Methods From January 2005 to January 2007,60 patients with nasopharyngeal carcinoma of stage m-IV b were received IMRT combined with concurrent chemotherapy in our center.Sixty patients were divided into paclitaxel concurrent group(32 patients)and cisplatin concurrent group(28 patients).The prescribing doses of the primary tumor were 68-72 Gy for each group.The patients of paclitaxel concurrent group patients of the cisplatin concurrent group got earlier radiodennatitis and radiation-induced mucositis but also got significantly higher rate of radiodermatitis,radiation-induced mucositis,radiation-induced leucopenia and gastrointestinal toxicity,as well as the loss of weight.No significant difference was found on liver and renal funcfons between two groups.Four patients(12.5%)of the paclitaxel concurrent group were broken-off,which was much better than the cisplatin concurrent group.There was no significant difference on the specific length of break-off time,the 2-year overall survival rate and the 2-year diseaee-free survival rate between two groups.Conclusions IMRT combined with concurrent chemotherapy of paclitaxel liposome for local advanced nasopharyngeal carcinoma results in less side-effects and better tolerance than IMRT combined with concurrent cisplatin chemotherapy.
